<unk>  is a hedgehog pathway inhibitor that is FDA approved for the treatment of metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.   Common adverse reactions include muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.
Vismodegib
Duvelisib
Enasidenib
Idelalisib
Ivosidenib
Brigatinib
Dalcetrapib
Evacetrapib